Novo Nordisk

News

Novo Nordisk has put $75 million down on the table to partner Canadian biotech Aspect Biosystems’ cell-based therapies for diabetes and obesity.

News

Novo Nordisk’s sought-after obesity drug Wegovy could be approved in the EU shortly for use in adolescents as well as adults.

Market Access

The price of insulin has become one of the most talked about issues across the pharma industry.

News

The two-year ban reflects "serious breaches” of the trade organisation’s code of practice.

News

Danish drugmaker says it will reduce the price of its insulin products in the US by up to 75%.

Market Access

Has the industry found a new revenue driver in weight-loss treatments?